What’s behind Indian pharma cos’ global acquisition spree
India's healthcare firms spent $4.32 billion during January to June of 2022 on mergers and acquisitions, compared to $2.02 billion in the same period last year
biocon 2
December 2022
October 2022
July 2022
January 2022
December 2021
November 2021
Biocon stock tumbles 12% in 5 sessions; here’s why
Biocon shares declined as much as 2.4% to ₹262.40 on Wednesday, hitting its lowest level since November 2019.
Sensex, Nifty to drop; Maruti, Tata Motors, Biocon, Axis Bank, Wipro, Tata Power eyed
Dalal Street is expected to see a subdued opening on Wednesday, tracking losses across Asia and Wall Street ahead of the U.S. Federal Reserve policy decision.
Sensex, Nifty to open flat; Adani Power, Biocon, YES Bank, NTPC, Marico shares eyed
The Sensex and the Nifty are set to open flat on Wednesday as mixed cues from global peers overshadowed a sharp fall in crude prices overnight.
Biocon developing 20 biosimilar products for global markets
Biocon, which launched the world's first interchangeable insulin Glargine in the US during the third quarter, has eight approved products.
Sensex, Nifty likely to stay in bear grip; RIL, HUL, Biocon, JSW Steel in focus
The BSE Sensex and the NSE Nifty are poised to open lower on Friday, following weak global cues and negative trends on SGX Nifty.
Sensex, Nifty to open higher; RIL, TCS, ICICI Bank, Adani Enterprises, Tata Steel in focus
The BSE Sensex and the NSE Nifty are expected to open higher on Monday as trends on SGX Nifty indicate a gap-up opening for the Indian share market.
Sensex, Nifty to open flat; CMS Info Systems, Biocon, SBI, Power Grid in focus
The BSE Sensex and the NSE Nifty are headed for a flat opening on Friday amid a mixed trend in global markets.
55 Indian pharma cos capable of mRNA vaccines
Almost every major Indian pharmaceutical company, including Cipla, Dr Reddy’s, Sun Pharma and Biocon, are on the list of companies which can produce mRNA Covid-19 vaccines
Walgreens to sell Biocon's insulin Semglee in the U.S.
Biocon Biologics targets to tap a $30 billion U.S. insulin market with two interchangeable insulins.
